Table I.
Patient demographics and disease characteristics of PsO, PsA and PsO/PsA patients who initiated etanercept or adalimumab at baseline.
| Patients initiating etanercept (n = 2,534) |
Patients initiating adalimumab (n = 1,919) |
|||||
|---|---|---|---|---|---|---|
| PsO (n = 1,609) |
PsA (n = 679) |
PsO/PsA (n = 246) |
PsO (n = 1,166) |
PsA (n = 518) |
PsO/PsA (n = 235) |
|
| Age, mean years (SD) | 45.5 (12.7) | 48.2 (11.0) | 47.9 (12.3) | 45.8 (12.1) | 47.6 (10.8) | 47.6 (11.8) |
| Sex, n women (%) | 690 (42.9) | 302 (44.5) | 103 (41.9) | 525 (45.0) | 248 (47.9) | 120 (51.1) |
| Geographic region, n (%) Northeast North Central South West Unknown |
161 (10.0) 456 (28.3) 708 (44.0) 277 (17.2) 7 (0.4) |
92 (13.5) 147 (21.6) 291 (42.9) 148 (21.8) 1 (0.1) |
32 (13.0) 60 (24.4) 100 (40.7) 51 (20.7) 3 (1.2) |
73 (6.3) 324 (27.8) 582 (49.9) 185 (15.9) 2 (0.2) |
77 (14.9) 111 (21.4) 241 (46.5) 89 (17.2) 0 |
20 (8.5) 58 (24.7) 126 (53.6) 30 (12.8) 1 (0.4) |
| Provider Specialty Rheumatologist Dermatologist Other Missing |
16 (1.0) 1262 (78.4) 291 (18.1) 40 (2.5) |
396 (58.3) 15 (2.2) 247 (36.4) 21 (3.1) |
86 (35.0) 70 (28.5) 80 (32.5) 10 (4.1) |
15 (1.3) 927 (79.5) 202 (17.3) 22 (1.9) |
301 (58.1) 14 (2.7) 192 (37.1) 11 (2.1) |
86 (36.6) 59 (25.1) 74 (31.5) 16 (6.8) |
| Charlson-Deyo Comorbidity Index, mean score (SD) | 0.20 (0.57) | 0.26 (0.73) | 0.22 (0.53) | 0.19 (0.60) | 0.19 (0.55) | 0.24 (0.62) |
| Comorbid conditions, n (%) Hypertensive disease Ischaemic heart disease* Conduction & rhythm disorders Heart failure Other heart disease Cerebrovascular disease Peripheral arterial disease Venous disease Other CV (non-heart) disease Diabetes Emphysema |
244 (15.2) 55 (3.4) 26 (1.6) 7 (0.4) 28 (1.7) 15 (0.9) 13 (0.8) 35 (2.2) 13 (0.8) 155 (9.6) 0 |
117 (17.2) 28 (4.1) 28 (4.1) 5 (0.7) 12 (1.8) 8 (1.2) 7 (1.0) 13 (1.9) 9 (1.3) 62 (9.1) 0 |
46 (18.7) 38 (15.4) 5 (2.0) 1 (0.4) 7 (2.8) 0 0 7 (2.8) 4 (1.6) 26 (10.6) 1 (0.4) |
191 (16.4) 16 (1.4) 32 (2.7) 7 (0.6) 26 (2.2) 10 (0.9) 7 (0.6) 24 (2.1) 13 (1.1) 106 (9.1) 4 (0.3) |
77 (14.9) 5 (1.0) 12 (2.3) 5 (1.0) 10 (1.9) 5 (1.0) 5 (1.0) 9 (1.7) 6 (1.2) 47 (9.1) 0 |
41 (17.4) 26 (11.1) 10 (4.3) 1 (0.4) 6 (2.6) 3 (1.3) 3 (1.3) 8 (3.4) 2 (0.9) 24 (10.2) 0 |
| Methotrexate use at baseline, n (%) | 167 (10.4) | 250 (36.8) | 77 (31.3) | 168 (14.4) | 240 (46.3) | 85 (36.2) |
*Coronary arterial disease.
PsO = Psoriasis; PsA = Psoriatic arthritis; PsO/PsA = Both psoriasis and psoriatic arthritis; CV = Cardiovascular.